Dundee University research find ADHD medication, Methylphenidate safe for long term treatment of ADHD
WHO had rejected Methylphenidate for inclusion in their Essential Medicines List due to concerns regarding the quality and limitations of the available data and evidence for both benefit and risk
An international study run by the University of Dundee has discovered that Methylphenidate is safe to use for long-term treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents.
The World Health Organization (WHO) rejected Methylphenidate for inclusion in their Essential Medicines List due to concerns regarding the quality and limitations of the available data and evidence for both benefit and risk. However, the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) project states that methylphenidate does not increase the risk of psychiatric or neurological adverse effects or growth impairments in children and adolescents.
Over the course of two years, approximately 1410 children from various child and adolescent mental health centres in the UK, Germany, Switzerland, Italy and Hungary participated in the project. According to the study, children taking methylphenidate grew at the same pace as children who did not and there was no adverse effect on their mental health.
Dr Sarah Inglis, from the University of Dundee’s School of Medicine, served as the project trial manager for the ADDUCE study. She stated, “The use of methylphenidate has gone up greatly since it was licensed in the 1950s and yet information about side effects from long-term use is scarce. We observed the characteristics of a large number of children with ADHD across Europe, including 274 from Dundee, taking methylphenidate over a period of two years. We compared these characteristics with children with ADHD not taking methylphenidate, and with children without ADHD. The study shows that the growth rate of children taking methylphenidate over two years was not different to that of children who were not.”
A statement from the University sates, “These findings of the ADDUCE study provide supportive evidence for the inclusion of methylphenidate on WHO’s Essential Medicines List, which would help increase the availability of the medicine and support more children around the world with ADHD.”
The University of Dundee is a key partner of the ADDUCE Consortium alongside several universities and institutions, including the University College London, the University of Hong Kong and the University of Melbourne.